What’s Behind the Obesity Epidemic

  • Carlotta Pozza
  • Andrea M. IsidoriEmail author


Obesity is defined as an abnormal or excessive accumulation of fat that may impair health, and it is a chronic disease that is increasing in prevalence [1]. It is now no exaggeration to state that obesity is an international epidemic. Moreover, it is no longer a disorder of the adult since obesity prevalence in children has accelerated rapidly. The etiology of obesity is multifactorial, involving a complex interaction among genetics, hormones, and the environment.Obesity is associated with increased risk of comorbidities such as type 2 diabetes mellitus, cardiovascular diseases, respiratory disorders, infertility, some forms of cancers, psychological and social problems and functional limitations, which can have a substantial, negative impact on quality of life; The risk of these comorbidities increases with further increase in BMI. The treatment of obesity and associated comorbidity is causing significant cost on the healthcare system.


Edmonton Obesity Staging System (EOSS) Obstructive Sleep Apnea Angiopoietin-like Protein (ANGPTL2) Nicotinamide Phosphoribosyltransferase (NAmPT) Polycystic Ovary Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bray GA, Ryan DH (2000) Clinical evaluation of the overweight patient. Endocrine 13:167–186CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Organization. Obesity and overweight. Fact Sheet No 311. 2015; Scholar
  3. 3.
    Fujioka K (2015) Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 17:1021–1032CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Corcelles R, Daigle CR, Schauer PR (2016) Management of endocrine disease: metabolic effects of bariatric surgery. Eur J Endocrinol 174:R19–R28CrossRefPubMedGoogle Scholar
  5. 5.
    James WPT, Jackson-Leach R, Ni Mhurchu C, Kalamara E, Shayeghi M, Rigby NJ, Nishida C, Rodgers A (2004) Overweight and obesity (high body mass index). In: Ezzati M, Lopez A, Rodgers A, CJL M (eds) Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. WHO, Geneva, pp 959–1108Google Scholar
  6. 6.
    De Lorenzo A, Soldati L, Sarlo F, Calvani M, Di Lorenzo N, Di Renzo L (2016) New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol 22:681–703CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tchernof A, Despres JP (2013) Pathophysiology of human visceral obesity: an update. Physiol Rev 93:359–404CrossRefPubMedGoogle Scholar
  8. 8.
    Sharma AM, Kushner RF (2009) A proposed clinical staging system for obesity. Int J Obes 33:289–295CrossRefGoogle Scholar
  9. 9.
    Guo F, Moellering DR, Garvey WT (2014) The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity 22:110–118CrossRefPubMedGoogle Scholar
  10. 10.
    Kaila B, Raman M (2008) Obesity: a review of pathogenesis and management strategies. Can J Gastroenterol 22:61–68CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709CrossRefPubMedGoogle Scholar
  12. 12.
    Schelbert KB (2009) Comorbidities of obesity. Prim Care 36:271–285CrossRefPubMedGoogle Scholar
  13. 13.
    Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C (2005) Effect of peptide yy3-36 on food intake in humans. Gastroenterology 129:1430–1436CrossRefPubMedGoogle Scholar
  14. 14.
    NHLBI OEIEPotI, Evaluation, and Treatment of Obesity in Adults (US) (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. National institutes of health. Obes Res 6(Suppl 2):51S–209SGoogle Scholar
  15. 15.
    Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696–4701CrossRefPubMedGoogle Scholar
  16. 16.
    Young LR, Nestle M (2002) The contribution of expanding portion sizes to the us obesity epidemic. Am J Public Health 92:246–249CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hubscher SG (2004) Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 16:1107–1115CrossRefPubMedGoogle Scholar
  18. 18.
    Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325CrossRefPubMedGoogle Scholar
  19. 19.
    Lee BC, Lee J (2014) Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta 1842:446–462CrossRefPubMedGoogle Scholar
  20. 20.
    Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Coope A, Torsoni AS, Velloso LA (2016) Mechanisms in endocrinology: metabolic and inflammatory pathways on the pathogenesis of type 2 diabetes. Eur J Endocrinol 174:R175–R187CrossRefPubMedGoogle Scholar
  22. 22.
    Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH (1978) Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 240:1607–1610CrossRefPubMedGoogle Scholar
  23. 23.
    Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8:605–619CrossRefPubMedGoogle Scholar
  24. 24.
    Re RN (2009) Obesity-related hypertension. Ochsner J 9:133–136PubMedPubMedCentralGoogle Scholar
  25. 25.
    Klop B, Elte JW, Cabezas MC (2013) Dyslipidemia in obesity: mechanisms and potential targets. Forum Nutr 5:1218–1240Google Scholar
  26. 26.
    Tchernof A, Lamarche B, Prud’Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP (1996) The dense ldl phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629–637CrossRefPubMedGoogle Scholar
  27. 27.
    Franssen R, Monajemi H, Stroes ES, Kastelein JJ (2011) Obesity and dyslipidemia. Med Clin North Am 95:893–902CrossRefPubMedGoogle Scholar
  28. 28.
    Wang H, Peng DQ (2011) New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis 10:176CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, American Heart A (2006) Obesity Committee of the Council on nutrition PA, metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 113:898–918CrossRefPubMedGoogle Scholar
  30. 30.
    Pasquali R, Casimirri F (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 39:1–16CrossRefGoogle Scholar
  31. 31.
    Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC (1999) The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535–582CrossRefPubMedGoogle Scholar
  32. 32.
    Pasquali R (2006) Obesity, fat distribution and infertility. Maturitas 54:363–371CrossRefPubMedGoogle Scholar
  33. 33.
    Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R (2002) Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26:883–896CrossRefPubMedGoogle Scholar
  34. 34.
    Pasquali R, Patton L, Gambineri A (2007) Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 14:482–487CrossRefPubMedGoogle Scholar
  35. 35.
    Saboor Aftab SA, Kumar S, Barber TM (2013) The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol 78:330–337CrossRefGoogle Scholar
  36. 36.
    Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D (2004) Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291:2978–2984CrossRefPubMedGoogle Scholar
  37. 37.
    Le Clanche S, Bonnefont-Rousselot D, Sari-Ali E, Rannou F, Borderie D (2016) Inter-relations between osteoarthritis and metabolic syndrome: a common link? Biochimie 121:238–252CrossRefPubMedGoogle Scholar
  38. 38.
    Malfait AM (2016) Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage 24:21–26CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hsu IR, Kim SP, Kabir M, Bergman RN (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:s867–s871PubMedGoogle Scholar
  40. 40.
    Ronti T, Lupattelli G, Mannarino E (2006) The endocrine function of adipose tissue: an update. Clin Endocrinol 64:355–365Google Scholar
  41. 41.
    de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P (2010) Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 178:230–235CrossRefPubMedGoogle Scholar
  42. 42.
    Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G (2014) On behalf of the Aace obesity scientific C. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 20:977–989CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ahrens W, De Henauw S, Buchecker K, de Lorgeril M, Fraterman A, Galli C, Iacoviello L, Krogh V, Mârild S, Molnár D, Moreno L, Palou A, Pitsiladis Y, Rayson MP, Reisch LA, Siani A, Tornaritis M, Veidebaum T, Wiliams GD, Fernandez L (2014) Prevalence of overweight and obesity in European children below the age of 10. Int J Obes (Lond). 38:S99–107. doi:  10.1038/ijo.2014.140.
  44. 44.
    Kushner RF, Blatner DJ (2005) Risk assessment of the overweight and obese patient. J Am Diet Assoc 105(5 Suppl 1):S53–62Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Experimental MedicineSapienza University of RomeRomeItaly

Personalised recommendations